Correction to: Fuzuloparib: First Approval

被引：0

|

作者：

Arnold Lee

机构：

[1] Springer Nature,

来源：

Drugs | 2021年 / 81卷 / 10期

关键词：

D O I：

10.1007/s40265-021-01570-6

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：1227 / 1227

相关论文

共 50 条

[21] Correction to: Oliceridine: First Approval
Anthony Markham
Drugs, 2020, 80 (17) : 1871 - 1871
[22] Correction to: Concizumab: First Approval
Susan J. Keam
Drugs, 2023, 83 (13) : 1253 - 1254
[23] Correction to: Abrocitinib: First Approval
Emma D. Deeks
Sean Duggan
Drugs, 2022, 82 (5) : 609 - 609
[24] Correction to: Regdanvimab: First Approval
Yahiya Y. Syed
Drugs, 2021, 81 (18) : 2139 - 2139
[25] Correction to: Satralizumab: First Approval
Young-A Heo
Drugs, 2020, 80 (14) : 1483 - 1483
[26] Correction to: Pexidartinib: First Approval
Yvette N. Lamb
Drugs, 2020, 80 (4) : 447 - 447
[27] Correction: Elacestrant: First Approval
Sheridan M. Hoy
Drugs, 2023, 83 (18) : 1735 - 1735
[28] Correction to: Ubrogepant: First Approval
Lesley J. Scott
Drugs, 2020, 80 (5) : 523 - 523
[29] Correction to: Lazertinib: First Approval
Sohita Dhillon
Drugs, 2021, 81 (10) : 1241 - 1241
[30] Correction to: Rozanolixizumab: First Approval
Sheridan M. Hoy
Drugs, 2023, 83 (16) : 1569 - 1569

← 1 2 3 4 5 →